	US 11,932,879 B2
	Mumps virus as a potential oncolytic agent
Mark J. Federspiel, Rochester, MN (US); Arun Ammayappan, Rochester, MN (US); Gennett Pike, Stewartville, MN (US); and Stephen James Russell, Rochester, MN (US)
Assigned to Mayo Foundation for Medical Education and Research, Rochester, MN (US)
Filed by Mayo Foundation for Medical Education and Research, Rochester, MN (US)
Filed on Jun. 23, 2022, as Appl. No. 17/847,629.
Application 17/847,629 is a continuation of application No. 16/747,782, filed on Jan. 21, 2020, granted, now 11,401,511.
Application 16/747,782 is a continuation of application No. 15/735,761, granted, now 10,577,591, issued on Mar. 3, 2020, previously published as PCT/US2016/036944, filed on Jun. 10, 2016.
Claims priority of provisional application 62/175,099, filed on Jun. 12, 2015.
Prior Publication US 2022/0348887 A1, Nov. 3, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 39/165 (2006.01); A61K 31/519 (2006.01); A61K 39/12 (2006.01); A61P 35/00 (2006.01); A61P 35/02 (2006.01); C12N 7/00 (2006.01); A61K 39/00 (2006.01)

CPC C12N 7/00 (2013.01) [A61K 31/519 (2013.01); A61K 39/12 (2013.01); A61K 39/165 (2013.01); A61P 35/00 (2018.01); A61P 35/02 (2018.01); A61K 2039/525 (2013.01); C12N 2760/18721 (2013.01); C12N 2760/18734 (2013.01)]

18 Claims

1. A recombinant mumps virus (MuV) having oncolytic anti-cancer activity, wherein said recombinant MuV comprises nucleic acid encoding an RNA polymerase large (L) subunit protein comprising a N to H substitution at amino acid 1631 as numbered in SEQ ID NO:10.